Genentech pulls breast cancer drug after FDA questions accelerated approval

The $8,000-a-month drug is still available for other types of cancer, but was voluntarily withdrawn by Genentech for metastatic triple-negative breast cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.